816 related articles for article (PubMed ID: 33230948)
21. Diffuse large B-cell lymphoma: new targets and novel therapies.
Cheson BD; Nowakowski G; Salles G
Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
[TBL] [Abstract][Full Text] [Related]
22. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis.
Ip A; Mutebi A; Wang T; Jun M; Kalsekar A; Navarro FR; Wang A; Kamalakar R; Sacchi M; Elliott B
Adv Ther; 2024 Mar; 41(3):1226-1244. PubMed ID: 38302846
[TBL] [Abstract][Full Text] [Related]
23. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
[TBL] [Abstract][Full Text] [Related]
24. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
25. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
Abdulhaq H; Hwang A; Mahmood O
Onco Targets Ther; 2023; 16():617-629. PubMed ID: 37492075
[TBL] [Abstract][Full Text] [Related]
26. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK; Watkins MP; Bartlett NL
Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
[TBL] [Abstract][Full Text] [Related]
27. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
Spinner MA; Advani RH
Oncology (Williston Park); 2022 Jan; 36(1):51-58. PubMed ID: 35089671
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
[TBL] [Abstract][Full Text] [Related]
29. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
[TBL] [Abstract][Full Text] [Related]
30. Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective.
Reddy NM; Thieblemont C
Ann Oncol; 2017 Nov; 28(11):2680-2690. PubMed ID: 29045503
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
33. Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
Varma G; Goldstein J; Advani RH
Hematol Oncol; 2023 Jun; 41 Suppl 1():92-106. PubMed ID: 37294966
[TBL] [Abstract][Full Text] [Related]
34. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
35. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J; Maddocks KJ; González-Barca E; Jurczak W; Liberati AM; De Vos S; Nagy Z; Obr A; Gaidano G; Abrisqueta P; Kalakonda N; André M; Dreyling M; Menne T; Tournilhac O; Augustin M; Rosenwald A; Dirnberger-Hertweck M; Weirather J; Ambarkhane S; Salles G
Haematologica; 2021 Sep; 106(9):2417-2426. PubMed ID: 34196165
[TBL] [Abstract][Full Text] [Related]
38. Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.
Sawalha Y
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945817
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
[TBL] [Abstract][Full Text] [Related]
40. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Davis JA; Shockley A; Glode AE
J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
